IDEXX LABS INC's ticker is IDXX and the CUSIP is 45168D104. A total of 1,082 filers reported holding IDEXX LABS INC in Q2 2024. The put-call ratio across all filers is 1.62 and the average weighting 0.2%.
About IDEXX LABS INC
IDEXX Laboratories, Inc. is a leading provider of diagnostic and information technology solutions for animal health. The company offers a wide range of products and services to veterinarians, livestock producers, and pet owners worldwide. IDEXX's mission is to enhance the health and well-being of pets, people, and livestock.
IDEXX's core business is in veterinary diagnostics, which includes blood and urine tests, digital imaging, and other diagnostic services. The company's products are used to diagnose and manage a variety of animal diseases, including cancer, heart disease, and infectious diseases.
IDEXX has a strong reputation for innovation and has been recognized for its contributions to the animal health industry. The company has received numerous awards for its products and services, including the Frost & Sullivan Company of the Year Award for Animal Health Diagnostics.
IDEXX has a strong financial position, with a market capitalization of over $30 billion. The company has consistently delivered strong financial results, with revenue growth of over 10% in the most recent quarter.
In conclusion, IDEXX Laboratories, Inc. is a leading provider of diagnostic and information technology solutions for animal health. The company has a strong reputation for innovation and has been recognized for its contributions to the animal health industry. With a strong financial position and consistent revenue growth, IDEXX is well-positioned for continued success in the future.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,291,513 | -9.8% | 4,703 | 0.0% | 0.27% | -8.8% |
| Q1 2024 | $2,539,252 | +4.1% | 4,703 | +7.0% | 0.30% | -4.2% |
| Q4 2023 | $2,439,992 | +26.7% | 4,396 | -0.2% | 0.31% | +13.2% |
| Q3 2023 | $1,925,839 | +164.2% | 4,404 | +97.9% | 0.27% | +274.0% |
| Q3 2022 | $728,838 | -2.8% | 2,225 | +1.6% | 0.07% | -1.4% |
| Q2 2022 | $749,694 | +180.2% | 2,189 | +347.6% | 0.07% | +89.7% |
| Q1 2022 | $267,513 | -16.0% | 489 | +1.0% | 0.04% | -9.3% |
| Q4 2021 | $318,553 | +2.2% | 484 | -3.4% | 0.04% | -6.5% |
| Q3 2021 | $311,564 | -29.2% | 501 | -28.0% | 0.05% | -30.3% |
| Q2 2021 | $439,773 | +32.8% | 696 | +2.8% | 0.07% | +20.0% |
| Q1 2021 | $331,195 | +2.3% | 677 | +4.5% | 0.06% | -6.8% |
| Q4 2020 | $323,751 | +26.0% | 648 | -0.9% | 0.06% | +11.3% |
| Q3 2020 | $256,969 | -11.6% | 654 | -25.7% | 0.05% | -22.1% |
| Q2 2020 | $290,692 | -20.5% | 880 | -24.7% | 0.07% | +58.1% |
| Q4 2019 | $365,699 | -0.8% | 1,168 | 0.0% | 0.04% | -6.5% |
| Q3 2019 | $368,802 | – | 1,168 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BOURNE LENT ASSET MANAGEMENT INC | 73,386 | $23,909,000 | 10.40% |
| CAPITAL COUNSEL LLC/NY | 489,232 | $159,392,000 | 10.32% |
| In-Depth Partners, LLC | 9,809 | $3,196,000 | 5.64% |
| FUNDSMITH INVESTMENT SERVICES LTD. | 997,876 | $325,108,000 | 5.62% |
| Fundsmith | 3,620,777 | $1,179,649,000 | 5.60% |
| AMERICAN CAPITAL MANAGEMENT INC | 383,347 | $124,894,000 | 4.93% |
| Westwind Capital | 42,282 | $13,775,000 | 4.83% |
| PERKINS CAPITAL MANAGEMENT INC | 10,805 | $3,520,000 | 3.94% |
| Blue Whale Capital LLP | 65,500 | $21,340,000 | 3.82% |
| Bridgecreek Investment Management, LLC | 53,295 | $17,364,000 | 3.71% |